Health ❯ Healthcare ❯ Oncology
Clinical Trials Pancreatic Cancer Survival Rates Innovative Therapies ESMO Congress 2025 KRAS Mutations RAS Mutations Combination Therapy Immunotherapy Early Detection Hepatocellular Carcinoma Soft Tissue Sarcomas Fundraising Biliary Tract Cancer Social Media Influence Clinical Guidelines Molecular Biology Epithelial Ovarian Cancer Biotechnology Prostate Cancer Precision Oncology Chemotherapy Resistance Immunotherapy Mechanisms Immunotherapy Enhancements Cancer-Associated Cachexia Mitochondrial Function Mortality Trends AIRC BET Inhibitors Innovative Techniques Ovarian Cancer Treatment Approvals Collaborative Education Triple-Negative Breast Cancer Society Española de Oncología Médica Biomarker Discovery Clinical Trials in Oncology Biomarkers New Molecules Glioblastoma CLDN18.2 Protein Tumor Immunology Metastasis ctDNA Tracking Tumor Treatment Pioneers in Cancer Care Immunotherapy Timing Protein Targeting RAS Protein Metastatic Cancer Pancreatic Adenocarcinoma Treatment Innovations Targeted Therapy New Drug Development RAS Proteins Molecular Genetics
Want to see what podcasts are saying about this topic? Search across 160K+ podcasts. Explore Radar
Roughly doubling median survival in a Phase 3 trial, the oral drug introduces a new treatment option that will prompt rapid clinical rollout, toxicity planning, and further studies.
